



Press Release

T-CURX announces \$20M Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral *in vivo* CAR-T platform

Würzburg, Germany - December 17, 2025

T-CURX GmbH (T-CURX) today announces the first closing of a \$ 20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for *in vivo* CAR-T generation.

The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.

Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX:

*"I am very excited that T-CURX attracted such a high-profile, international investor's syndicate, led by BiomedVC, for financing T-CURX's non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets. It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable *in vivo* CAR-T generation, in order to "democratize" CAR-T therapies for patients globally."*

Aristotelis Nastos, PhD, Managing Partner and investment director at lead-investor BiomedVC adds:

"I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track-record and experience of T-CURX Founder's and Management team and the promise of T-CURX non-viral CAR-T technologies hold for making CAR-T therapies accessible and affordable for many cancer patients globally. We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions"

T-CURX is a German Biotech company located in Würzburg and Munich, Germany, spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, University of Würzburg, who is a European KOL and pioneer in the development and clinical translation of non-viral CAR-T cell therapies to target various types of cancer.

About T-CURX

T-CURX is a privately owned, German Biotech company based in Würzburg founded in 2017 with the vision of bringing next-generation CAR-T cell therapies manufactured with cost-effective and highly scalable non-viral CAR-T cell technologies to more cancer patients in need of more effective cancer therapies. T-CURX was spun out of the laboratory of T-CURX co-founder Prof. Michael Hudecek at the University of Würzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. T-CURX leverages a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing based on virus-free, Sleeping-beauty transposon gene transfer into patient's T cells. For more information about T-CURX visit the web-site www.t-curx.com

About BiomedVC

BiomedVC is a leading Swiss early-stage VC at the center of European biotech. BiomedVC builds companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality - as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient's lives.

-end-

For further information: Ulf

Grawunder, CEO

E-Mail: ulf@t-curx.com

For media enquiries:

Phone: +49-(0)-931-250-99-712

E-mail: pr@t-curx.com